Revised summary: The event marked a shift to commercialization, with Flora Sync LF5 and DARE to PLAY Sildenafil Cream launching in 2024. The pipeline features Ovaprene (phase III), DARE-HPV (phase II), and menopause solutions, backed by non-dilutive funding and a digital-native model. Key milestones: commercial traction and clinical data in 2025–2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.